|Patent # ||Subject ||Assignee(s) ||Inventor(s) ||Priority application date ||Publication date |
|WO 200589792 || |
A new recombinant protein comprising polypeptides bearing epitopes of human papilloma virus (HPV) antigens; useful for treating or preventing HPV infection, or for immunotherapy against the onset of malignant transformation due to HPV infection.
|BT Pharma (Labège-Innopole, France); INSERM (France); Institut Pasteur (Paris); CNRS (France) ||la Dant D, le Clerc C, Preville X, Timmerman B ||3/18/2004 ||9/29/2005 |
|WO 200587813 || |
A new composition that comprises contacting an antigen-presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, which comprises a xenotypic antibody fragment; useful for eliciting a T-cell response against hepatitis B virus and hepatitis C virus infections.
|ViRexx (Edmonton, Alberta, Canada) ||George R, Noujaim A, Tyrrell L, Wang D ||2/24/2004 ||9/22/2005 |
|WO 200587799 || |
A new isolated polypeptide that binds specifically to an oligosaccharide; useful in preparing a vaccine for treating or preventing HIV infection.
|US Dept. of Health & Human Services (Washington, DC, USA) ||Bewley CA ||3/9/2004 ||9/22/2005 |
|US 20050202045 || |
A method for making a recombinant avian herpesvirus, comprising cotransfecting overlapping subgenomic fragments employing the subgenomic clones and enzymes; useful in producing therapeutic or prophylactic vaccines.
|Schering-Plough Veterinary Corp. (Kenilworth, NJ, USA) ||Cochran MD, Cook SM, Wild MA ||6/14/2001 ||9/15/2005 |
|WO 200585445 || |
A novel recombinant varicella herpes-zoster virus comprising a bacterial artificial chromosome vector sequence; useful as a vaccine for treating varicella herpes-zoster virus infection.
|Osaka University (Osaka, Japan) ||Gomi Y, Mori Y, Nagaike K, Takahashi M, Yamaishi K ||3/5/2004 ||9/15/2005 |
|EP 1574517 || |
A novel recombinant or synthetic hepatitis C virus E1 envelope protein or its portion comprising one or more disulfide bonds between a specific pair of cysteines; useful as vaccine for hepatitis C virus.
|Innogenetics (Ghent, Belgium) ||Bosman A, Depla E, Depraetere S, Verheyden G ||3/9/2004 ||9/14/2005 |
|WO 200581716 || |
A novel nucleic acid encoding chimeric polypeptides such as calreticulin and antigenic peptide from severe acute respiratory syndrome (SARS) coronavirus; useful as a DNA vaccine for SARS coronavirus.
|Johns Hopkins University (Baltimore, MD, USA) ||Hung C, Kim TW, Wu T ||11/24/2003 ||9/9/2005 |
|CN 1616654 || |
A method for inactivating and purifying SARS virus; useful for preparing vaccines to combat SARS.
|Kexing Biological Products (Shenzen, China) ||Han Z, Zhang J, Zhang Z ||11/12/2003 ||5/18/2005 |
|CN 1616491 || |
A new fusion protein useful as a vaccine for treating and preventing influenza.
|Qinghua University (Beijing) ||Chen Y; Liu W ||9/29/2004 ||5/18/2005 |
|CN 1614011 || |
A totally enclosed double-circulating column chromatography process for purifying inactivated virus vaccines.
|Jiahe Biotechnology (Guangzhou, China) ||He C; Le W ||11/6/2003 ||5/11/2005 |
|CN 1613503 || |
A technique for preparing a virus vaccine using a bioreactor featuring a disk carrier for increasing the surface area used to grow cells, and a better culture condition created for increasing the culture density.
|Jiahe Biotechnology (Guangzhou, China) ||He C, Zhang J ||11/6/2003 ||5/11/2005 |
|IN 200200194 ||Liposomes containing novel peptide antigens; useful for regulating the immune response and for the development of therapeutic agents for the prevention and treatment of hepatitis B virus–associated diseases. ||Mogam Biotechnology Research Institute (Yongin, South Korea) ||Chang JS, Cheong H, Cho SY, Choi MJ, Hwang Y, Kim TY, Lee KU ||4/3/2002 ||3/11/2005 |